Recovery from COVID-19 in a B-cell-depleted multiple sclerosis patient

Approximately 200,000 multiple sclerosis (MS) patients worldwide receive B-cell-depleting immunotherapy with rituximab (anti-CD20), which eliminates the ability to generate an antibody response to new infections. As severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)–specific antibodies mig...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Mult Scler
Huvudupphovsmän: Wurm, Hannah, Attfield, Kate, Iversen, Astrid KN, Gold, Ralf, Fugger, Lars, Haghikia, Aiden
Materialtyp: Artigo
Språk:Inglês
Publicerad: SAGE Publications 2020
Ämnen:
Case Report and Clinical Commentary
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7502978/
https://ncbi.nlm.nih.gov/pubmed/32762494
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1352458520943791
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk